Aydin S.Z.Direskeneli H.Merkel P.A.Toloza S.Blockmans D.Sato E.I.De Souza A.W.S.2024-06-122024-06-1220170315-162Xhttps://doi.org/10.3899/jrheum.161269https://hdl.handle.net/20.500.14551/16684Objective. To arrive at consensus for candidate outcomes for disease activity assessment in largevessel vasculitis (LVV) in clinical trials. Methods.A Delphi survey including 99 items was circulated among international experts for 3 rounds. Results. Fifty-seven items were accepted for both giant cell arteritis and Takayasu arteritis. Sixty-seven percent of experts voted to have a common approach for both diseases with additional disease-specific items such as weight loss, scalp tenderness/necrosis, morning stiffness, dizziness, visual symptoms, and imaging. Conclusion. This study highlights similarities and differences in experts' perspectives for assessing clinical activity in LVV and may guide a consensus-driven core set of validated outcomes. Copyright © 2017. All rights reserved.en10.3899/jrheum.161269info:eu-repo/semantics/openAccessGiant Cell Arteritis; Large Vessel; Outcomes; Takayasu Arteritis; VasculitisAortic Arch Syndrome; Article; Blood Vessel Diameter; Clinical Outcome; Consensus; Delphi Study; Disease Activity; Dizziness; Giant Cell Arteritis; Health Survey; Human; International Cooperation; Large Vessel Vasculitis; Medical Expert; Musculoskeletal Stiffness; Outcome Assessment; Priority Journal; Skin Necrosis; Vasculitis; Visual Disorder; Weight Reduction; Aortic Arch Syndrome; Giant Cell Arteritis; Severity Of Illness Index; Delphi Technique; Giant Cell Arteritis; Humans; Severity Of Illness Index; Takayasu ArteritisArticle4412192819322-s2.0-8503709416128864648Q1